A radioreceptor assay for chlorpromazine in serum, which is based on binding to dopamine receptors, is described. This method has been postulated to measure all active metabolites as well as the parent drug. We have compared this method with an HPLC method for chlorpromazine. Dopamine-blocking activity, measured in serum samples from schizophrenic patients receiving chlorpromazine, was 1·85 -9·1 times higher than serum chlorpromazine level measured by HPLC. The correlation between the two methods was 0·75. Dopamine-blocking activity was related more closely to dose of drug and to serum prolactin level than was serum chlorpromazine level measured by HPLC.
As neuroleptic drugs are thought to act through blockade of central dopamine receptors, I this property has been used to develop a radioreceptor assay' which may be more relevant to clinical effects. Central dopaminergic blockage also results in increased prolactin release, and measurement of serum prolactin has been postulated to relate to clinical effects. J . This paper describes a preliminary study in which three parameters, namely the serum levels of chlorpromazine, as measured by highpressure liquid chromatography (HPLC), and prolactin and the serum dopamine-receptor blocking activity, are related to each other and to daily dose of drug in chronically ill psychotic patients undergoing treatment with chlorpromazine.
Methods HIGH-PRESSURE LIQUID CHROMATOGRAPHY HPLC was performed using an Applied Chromatography Systems pump fitted with a Rheodyne valve loop injector (10 ilL) connected to an EDT Research Model LCA 15 electro-chemical detector. The mobile phase, 35% 0·02 mol/L potassium phosphate buffer, pH 6, in acetonitrile, was pumped at 2 mUmin through a 12·5 cmx4·9 mm i.d. column packed with Spherisorb S5CN. Chlorpromazine HCI (May & Baker, Dagenham, Essex, UK) standards were made up in pooled human serum. Standards and patient samples were extracted using a method based on that of Wallace et al." for phenothiazines. Serum (0,2 mL) was placed in a glass tube, 0·01 g of sodium carbonate added, vortexed, then 1 mL hexane containing 4% butan-2-ol and (+ )-butaclamol (Research Biochemicals Incorporated, Wayland, MA, USA) 500· ng/mL as internal standard. After shaking for 15 min, the upper organic layer was transferred to a conical tube and evaporated to dryness at 50°C under nitrogen-air flow. The residue was redissolved in 50 ILL of methanol and 10 ILL injected onto the column.
RADIORECEPTOR ASSAY FOR

DOPAMINE-BLOCKING ACTIVITY
This radioreceptor (RRA) method has been described in detail elsewhere" and is based on that of Cohen, Herschel and Aoba." Essentially, caudate nuclei from calf brains are used as a source of dopamine receptors to which 3H-spiroperidol is added. Specific binding. of the ligand to dopamine receptors is defined as the difference in binding in the presence or absence of a large excess of (+ )-butaclamol. This may be inhibited by neuroleptic drugs as they compete with 3H-spiroperidol for receptor sites. Chlorpormazine HCI inhibits specific dopamine receptor binding with an IC50 or 28·3 ng/mL in the presence of 15D ul, pooled human serum. Measurement of the dopamineblocking activity in serum is achieved by comparison of the inhibition of binding to that of a series of standard concentrations using a loglogit plot, similar to that used for most radioimmunoassays. The resultant value may be expressed in any units; here ng/mL chlorpromazine is used to facilitate comparisons and for recovery experiments. However, it must be noted that in serum from patients, the value obtained will be made up of chlorpromazine plus metabolites. Specificity of the HPLC method was checked against other neuroleptic agents. No interference was found with the exception of fluphenazine. None of the patients in this study was receiving fluphenazine.
SERUM PROLACTIN
Prolactin levels were measured by radioimmunoassay using a kit (Chelsea Hospital for Women, London, UK).
PATIENTS' SAMPLES
Serum chlorpromazine, dopamine-blocking ac-
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tivity and prolactin were measured in samples from 17 male in-patients of Prestwich Hospital, diagnosed as suffering from chronic schizophrenia. Chlorpromazine in tablet form had been administered long term to all patients by nursing staff on a once or twice daily basis. One sample was drawn from each patient at least 8 h after the last dose (between 4 and 5 p.m.) after at least 8 days constant dosage. Only one patient was receiving additional concurrent medication (nitrazepam 10 mg nocte). Ten mL of venous blood was taken from the antecubital vein, allowed to clot, and the serum transferred to separate tubes for each assay, then frozen until assayed. No reduction in concentration has been found to occur with any of the assays after prolonged storage of samples.
Results
HPLC
The HPLC system used had good sensitivtty to chlorpromazine, and levels of 5 ng/mL in patients' samples were measurable. Mean recovery of chlorpromazine from standards was 86·9+5·97% (SD) as assessed by comparison with peak height of standards in methanol. The within-batch recoveries are given in Table 1 . The samples from all 17 patients had measurable levels of chlorpromazine, ranging from 8·8 to 114·5 ng/mL (Table 3) . Each patient's sample was extracted and assayed twice on different days, the between-batch CV of duplicates being 11·4%. RRA The RRA method was not as sensitive as HPLC, the theoretical minimum detection limit being 11·5 ng/mL (defined as that concentration producing 15% inhibition of specific 3H-spiroperidol binding, since below this, non-linearity of the standard curve occurs). However, dopamine-blocking activity was measured in all but two ofthe patients' samples, at much higher levels than those found by HPLC, 28·3-289·6 ng/mL (Table 3 ). Recovery from spiked samples averaged 113·7%+20·5% (SD), the greatest variation being found at low levels ( Table 2 ). The between-batch CV of duplicate assays on the 17 patients' samples was 13·8%. PROLACTIN Reproducibility of the radioimmunoassay kit was assessed by the inclusion of pooled quality control samples of unknown concentration in each assay. The CV ranged from 6·8 to 9·3% over the concentration ranges 160 to 820 mIUIL. Prolactin levels in normal volunteers were 90-250 in 14 women and 88-215 in nine men. Similar levels (88-290, n=14) were found in a group of long-term psychiatric in-patients not diagnosed as schizophrenic, receiving antidepressants, anti-convulsants or benzodiazepines.
Of the 17 samples from patients receiving chlorpromazine, eight (47%) had prolactin levels above those found in the normal population, but only six (35%) had levels higher than those in other psychiatric patients. The prolactin levels in chlorpromazine-treated patients ranged from 110 to 1470 mIUIL (Table 3) . RELATIONSHIPS The levels of dopamine-blocking activity in the samples, when expressed in terms of ng/ml, chlorpromazine, were moderately well correlated with the chlorpromazine level measured by HPLC (r=0·746, P<0'()()()5), although the former were on average 4·75 times higher than the latter (range 1·85-9·15, n=15; Fig. 1 ). One of the reasons for this difference is that the dopamine-binding assay measures all metabolites which bind to the receptor as well as chlorpromazine itself. However, in two samples where low levels were found by HPLC there was no measurable level by the RRA. Prolactin levels were not related to chlorpromazine levels measured by HPLC (r=0·277) but were weakly correlated with dopamineblocking activity (r=0·543, P<0·025).
Both chlorpromazine concentration and dopamine-blocking activity were related to the daily dose of drug, although the relationship appeared to be much closer for RRA (r=0·957, P<0·OO(5) than for HPLC (r=0'674, P<0·(05) (Fig 2) . However, there was considerable variation in the levels found in different patients on the same dose with both methods. This was greatest at low dosages using RRA (0-49 ng/mL for patients on 100 mg/day) and at high dosages using HPLC (21-87 ng/mL for patients on 700 mg/day). Dose of chlorpromazine was poorly related to serum prolactin (r=0·416, P<0·05). There was no difference between patients with normal or raised prolactin levels with respect to dosage.
Discussion
The HPLC method was sufficiently sensitive to measure chlorpromazine in serum from all 17 patients using a small sample volume and a relatively simple extraction procedure. Many workers in the past have experienced problems in preparing samples for assay, resulting in complex extraction procedures and/or large sample volumes," 8 while not always achieving reasonable recovery. 7 • 9 However, the method is fairly time-consuming, allowing a maximum of 20 samples/day to be assayed.
The RRA method is simpler and quicker to perform, since no extraction is required and a considerably higher throughput can be achieved (100 samples/day), although counting time must be added to this. A further advantage of this assay is its adaptability to all neuroleptics. However, it was found to be less sensitive than HPLC and reproducibility was poor at low levels. The concentrations measured by RRA were higher than corresponding levels measured by HPLC. This may be explained by the measurement by the RRA method of metabolites, since the major active metabolites of chlorpromazine are known to bind to the calf caudate dopamine receptor, while inactive ones do not."
There is a wide variation among the samples in the proportion of dopamine-blocking activity which can be ascribed to chlorpromazine. Although the difference between results by the two methods may be exaggerated by different recoveries, active metabolites do appear to account for a large proportion of dopamineblocking activity in many patients. This is supported by the work of Sakalis et al. • Both the dopamine-blocking activity and the' chlorpromazine level were related to daily dose of drug. A higher degree of correlation was found with RRA (,=0·96) than with HPLC (,=0·67), although there was variation between samples from different patients on the same dose with both methods. This was most pronounced at low levels with the RRA, which may be a reflection of the relatively poor precision of the method at low concentrations. Using GLC methods, many other workers have found no correlation between dosage and serum levels. 12-14 However, correlations have been found using RRA methods. IS. 16 This reinforces the potential importance of measuring active metabolites in addition to parent drug."
A relationship between the serum levels of prolactin and neuroleptics has been found by several workers in both acute and chronic patients using various methods of drug assay.17-21J In most chronically-treated patients, prolactin levels are thought to vary only slightly over periods of days, weeks or months, hence a single sample was used for comparison with the neuroleptic levels. The serum prolactin level was weakly related to dopamine-blocking activity (,=0·54), but not at all to the HPLC results (,=0·28). This difference may again be due to the influence of active metabolites, although the many additional factors known to affect prolactin levels require that the results be viewed with caution.
Interestingly, however, approximately 50% of the patients in our study did not have raised prolactin levels despite high neuroleptic dosage and/or high activity in the RRA. This is in agreement with the work of Nakahara et at. 16 and of Kolakowska et at. 13 and is the most likely cause of the poor correlation between prolactin levels, neuroleptic levels and dosage. This leads to the suggestion that in chronic patients, who may have developed tolerance to the prolactin response to neuroleptics, measurement of serum prolactin concentration may not reflect central anti-dopaminergic activity.
Nonetheless, the closer relationship of serum dopamine-blocking activity with both prolactin level and dosage in this preliminary study may be an indication that this is a more appropriate parameter to study further than is the serum chlorpromazine level. Several studies have noted that metabolites play an important role in the clinical effectiveness of chlorprcmazine": 22 and the RRA offers a simple means of assay for the parent drug and all active metabolites.
